Chiesi are committed to finding breakthrough solutions to meet the unmet needs and improve the lives of patients with Rare Diseases.
Chiesi are industry pioneers in regenerative medicine, with the first ever stem-cell based therapy approved in the EU1 and the first to receive a positive NICE recommendation in England2
From drug discovery to patient access to medicine, The UK Rare Disease team will strive to work with patient organisations, clinicians and the wider healthcare system to help create a brighter future for patients with Rare Diseases.
References
UK-CHI-1800066 December 2018
